Distinct Sets of Genetic Alterations in Melanoma
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. METHODS: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. RESULTS: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. CONCLUSIONS: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While these mutations are not UV-signature mutations20, they are more common in sun-exposed skin20–23.”
From Mechanisms and prevention of UV‐induced melanoma (2018) · cites this paper as [20]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
R: A Language for Data Analysis and Graphics
Ihaka, R., & Gentleman, R. (1996) · Journal of Computational and Graphical Statistics · doi:10.1080/10618600.1996.10474713 · Cited by 11,220
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Comparison of Discrimination Methods for the Classification of Tumors Using Gene Expression Data
Dudoit, S., Fridlyand, J., & Speed, T. P. (2002) · Journal of the American Statistical Association · doi:10.1198/016214502753479248 · Cited by 2,672
Self-citationPinkel, D., Segraves, R., Sudar, D., Clark, S., Poole, I., Kowbel, D., Collins, C., Kuo, W.-L., Chen, C., Zhai, Y., et al. (1998) · Nature Genetics · doi:10.1038/2524 · Cited by 2,240
Self-citationThe histogenesis and biologic behavior of primary human malignant melanomas of the skin.
Clark, W. H., From, L., Bernardino, E. A., & Mihm, M. C. (1969) · PubMed · Cited by 2,112
High frequency of BRAF mutations in nevi
Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., et al. (2003) · Nature Genetics · doi:10.1038/ng1054 · Cited by 1,730
Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment.
Martin, M. A., Westfall, P. H., & Young, S. S. (1994) · Biometrics · doi:10.2307/2533464 · Cited by 1,699
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
Serrano, M., Lee, H.-W., Chin, L., Cordon-Cardo, C., Beach, D., & DePinho, R. A. (1996) · Cell · doi:10.1016/s0092-8674(00)81079-x · Cited by 1,585
LOWESS: A Program for Smoothing Scatterplots by Robust Locally Weighted Regression
Cleveland, W. S. (1981) · The American Statistician · doi:10.2307/2683591 · Cited by 1,150
Cited by
Items 901–1,000 of 1,006
Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma
Monti, M., Consoli, F., Vescovi, R., Bugatti, M., & Vermi, W. (2020) · Cells · doi:10.3390/cells9020417 · Cited by 43
Efficacy of immune checkpoint inhibitors in different types of melanoma
Rossi, E., Schinzari, G., Maiorano, B. A., Indellicati, G., Stefani, A. D., Pagliara, M. M., Fragomeni, S. M., Luca, E. V. D., Sammarco, M. G., Garganese, G., et al. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1771986 · Cited by 44
The gut microbiome and melanoma: A review
Makaranka, S., Scutt, F., Frixou, M., Wensley, K. E., Sharma, R., & Greenhowe, J. (2022) · Experimental Dermatology · doi:10.1111/exd.14639 · Cited by 44
Spanjaard, R. A., Whren, K., Graves, C., & Bhawan, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22367 · Cited by 42
Effect of individual and neighborhood socioeconomic status on oral cancer survival
Lee, C., Chien, S., Hung, S., Yang, W.-Z., & Su, Y. (2011) · Oral Oncology · doi:10.1016/j.oraloncology.2011.10.002 · Cited by 42
Oncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract
Tseng, D., Kim, J. J., Warrick, A., Nelson, D., Pukay, M., Beadling, C., Heinrich, M. C., Selim, M. A., Corless, C. L., & Nelson, K. C. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.03.033 · Cited by 42
AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX–MDM2 complex
de Polo, A., Luo, Z., Gerarduzzi, C., Chen, X., Little, J. B., & Yuan, Z.-M. (2016) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw045 · Cited by 43
AMPK promotes survival of c‐Myc‐positive melanoma cells by suppressing oxidative stress
Kfoury, A., Armaro, M., Collodet, C., Sordet‐Dessimoz, J., Giner, M. P., Christen, S., Moco, S., Leleu, M., de Leval, L., Koch, U., et al. (2018) · The EMBO Journal · doi:10.15252/embj.201797673 · Cited by 42
Cutaneous melanoma: Taiwan experience and literature review.
Chang, J. W. (2010) · PubMed · Cited by 42
Latest Approved Therapies for Metastatic Melanoma: What Comes Next?
Menaa, F. (2013) · Journal of Skin Cancer · doi:10.1155/2013/735282 · Cited by 41
New Strategies in Metastatic Melanoma: Oncogene-Defined Taxonomy Leads to Therapeutic Advances
Flaherty, K. T., & Fisher, D. E. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2612 · Cited by 41
Terada, T. (2010) · International Journal of Clinical Oncology · doi:10.1007/s10147-010-0087-0 · Cited by 41
TERT gene amplification is associated with poor outcome in acral lentiginous melanoma
Díaz, A., Puig‐Butillé, J. A., Muñoz, C., Costa, D., Díez, A., García‐Herrera, A., Carrera, C., Bádenas, C., Solé, F. G., Malvehy, J., et al. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2014.05.035 · Cited by 41
Sinha, R., Larkin, J., Gore, M. E., & Fearfield, L. A. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13958 · Cited by 41
Bidshahri, R., Attali, D., Fakhfakh, K., McNeil, K., Karsan, A., Won, J., Wolber, R. A., Bryan, J., Hughesman, C. B., & Haynes, C. A. (2016) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.09.003 · Cited by 41
Copy number variations in atypical fibroxanthomas and pleomorphic dermal sarcomas
Helbig, D., Quaas, A., Mauch, C., Merkelbach‐Bruse, S., Büttner, R., Emberger, M., Wobser, M., Rüsseler, V., Pütz, K., Binot, E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22691 · Cited by 41
Sauter, D., Lodde, G. C., Nensa, F., Schadendorf, D., Livingstone, E., & Kukuk, M. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107083 · Cited by 41
Clinical relevance of Neutral Endopeptidase (NEP/CD10) in melanoma
Velázquez, E. F., Yancovitz, M., Pavlick, A. C., Berman, R. S., Shapiro, R. L., Bogunovic, D., O’Neill, D. W., Yu, Y.-L., Spira, J., Christos, P. J., et al. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-2 · Cited by 41
The value of screening in melanoma
Stratigos, A., & Katsambas, A. (2008) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2008.09.002 · Cited by 41
Latitude gradient for melanoma incidence by anatomic site and gender in Norway 1966–2007
Micu, E., Juzeniene, A., Porojnicu, A. C., Bruland, Ø. S., & Moan, J. E. (2010) · Journal of Photochemistry and Photobiology B Biology · doi:10.1016/j.jphotobiol.2010.04.002 · Cited by 41
Targeted Therapy in Older Patients With Solid Tumors
Kelly, C. M., Power, D. G., & Lichtman, S. M. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.4246 · Cited by 41
Cho‐Vega, J. H. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.70 · Cited by 41
Barbano, R., Pasculli, B., Coco, M., Fontana, A., Copetti, M., Rendina, M., Valori, V. M., Graziano, P., Maiello, E., Fazio, V. M., et al. (2015) · Scientific Reports · doi:10.1038/srep18592 · Cited by 41
The genetics of malignant melanoma
Lomas, J., Martín‐Duque, P., Pons, M., & Quintanilla, M. (2008) · Frontiers in bioscience · doi:10.2741/3065 · Cited by 42
Perrot, C. Y., Gilbert, C., Marsaud, V., Postigo, A. A., Javelaud, D., & Mauviel, A. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12149 · Cited by 40
Todd, J. R., Becker, T. M., Kefford, R. F., & Rizos, H. (2013) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12107 · Cited by 40
Melanoma Mutagenesis and Aberrant Cell Signaling
Bello, D. M., Ariyan, C. E., & Carvajal, R. D. (2013) · Cancer Control · doi:10.1177/107327481302000404 · Cited by 40
The molecular pathology of cutaneous melanoma
Bogenrieder, T., & Herlyn, M. (2011) · Cancer Biomarkers · doi:10.3233/cbm-2011-0164 · Cited by 41
Bonner, M. Y., Karlsson, I. B., Rodolfo, M., Arnold, R. S., Vergani, E., & Arbiser, J. L. (2016) · Oncotarget · doi:10.18632/oncotarget.7289 · Cited by 40
Patel, B. G., Ahmed, K. A., Johnstone, P. A. S., Yu, H.-H. M., & Etame, A. B. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000250 · Cited by 40
Ashida, A., Sakaizawa, K., Uhara, H., & Okuyama, R. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2748 · Cited by 40
Melanoma of the eyelid and periocular skin: Histopathologic classification and molecular pathology
Mancera, N., Smalley, K. S. M., & Margo, C. E. (2018) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2018.12.002 · Cited by 40
Genomic and transcriptomic landscape of conjunctival melanoma
Cisarova, K. V., Folcher, M., Zaoui, I. E., Gobert, R. P., Peter, V. G., Royer‐Bertrand, B., Zografos, L., Schalenbourg, A., Nicolas, M., Rimoldi, D., et al. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1009201 · Cited by 42
Lee, J. H., Choi, Y. D., Hwang, J. H., Shin, M., & Yun, S. J. (2021) · Annals of Dermatology · doi:10.5021/ad.2021.33.3.228 · Cited by 40
Biological challenges of BRAF inhibitor therapy
Puzanov, I., Burnett, P., & Flaherty, K. T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.01.005 · Cited by 36
The DNA Damage-Binding Protein XPC Is a Frequent Target for Inactivation in Squamous Cell Carcinomas
de Feraudy, S. M., Ridd, K., Richards, L. M., Kwok, P., Revet, I. M., Oh, D. H., Feeney, L., & Cleaver, J. E. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090925 · Cited by 40
Rutkowski, P. L., Gos, A., Jurkowska, M., Świtaj, T., Dziewirski, W., Zdzienicki, M., Ptaszyński, K., Michej, W., Tysarowski, A., & SIEDLECKI, J. A. (2014) · Oncology Letters · doi:10.3892/ol.2014.2122 · Cited by 40
Melanoma: patogénesis, clínica e histopatología
Acosta, Á. E., Fierro, E., Velásquez, V. E., & Rueda, X. (2009) · Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica · Cited by 40
Posch, C., Sanlorenzo, M., Vujic, I., Osés-Prieto, J. A., Cholewa, B. D., Kim, S. T., Ma, J. A., Lai, K., Zekhtser, M., Esteve‐Puig, R., et al. (2016) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2016.05.098 · Cited by 40
RGS1 expression is associated with poor prognosis in multiple myeloma
Roh, J., Shin, S., Lee, A.-N., Yoon, D. H., Suh, C., Park, C., Huh, J., & Park, C.-S. (2016) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2016-203713 · Cited by 40
Puccio, F. B., & Chian, C. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2010-0323-rar.1 · Cited by 39
Advanced Malignant Melanoma: Immunologic and Multimodal Therapeutic Strategies
Halama, N., Zoernig, I., & Jaeger, D. (2010) · Journal of Oncology · doi:10.1155/2010/689893 · Cited by 39
Grunsven, A. C. H. V. E., Küsters‐Vandevelde, H. V. N., Groenen, P. J. T. A., & Blokx, W. A. M. (2014) · Frontiers in Medicine · doi:10.3389/fmed.2014.00039 · Cited by 39
Gottesdiener, L. S., O'Connor, S., BUSAM, K. J., Won, H. H., Solit, D. B., Hyman, D. M., & Shoushtari, A. N. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1397 · Cited by 39
Self-citationTumor genetic heterogeneity analysis of chronic sun‐damaged melanoma
Sanna, A. M., Harbst, K., Johansson, I., Christensen, G. B., Lauss, M., Mitra, S., Rosengren, F., Häkkinen, J., Vallon‐Christersson, J., Olsson, H. L., et al. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12851 · Cited by 39
Emerging strategies to treat rare and intractable subtypes of melanoma
Alicea, G. M., & Rebecca, V. W. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12880 · Cited by 39
The tumor genetics of acral melanoma: What should a dermatologist know?
Tod, B., Schneider, J. W., Bowcock, A. M., Visser, W. I., & Kotze, M. J. (2020) · JAAD International · doi:10.1016/j.jdin.2020.07.004 · Cited by 40
Non-coding RNAs in melanoma: Biological functions and potential clinical applications
Qiu, P., & Wang, J. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.012 · Cited by 40
Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis
Kolla, A. M., Vitiello, G. A., Friedman, E. B., Sun, J. X., Potdar, A., Daou, H., Farrow, N. E., Farley, C. R., Vetto, J. T., Han, D., et al. (2021) · Cancer Control · doi:10.1177/10732748211053567 · Cited by 40
Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?
Lelliott, E. J., Sheppard, K. E., & McArthur, G. A. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00273-9 · Cited by 39
Paolino, G., Didona, D., Macrì, G., Calvieri, S., & Mercuri, S. R. (2018) · Codon Publications eBooks · doi:10.15586/codon.noncutaneousmelanoma.2018.ch6 · Cited by 39
CHEK2*1100delC and Risk of Malignant Melanoma: Danish and German Studies and Meta-Analysis
Weischer, M., Heerfordt, I. M., Bojesen, S. E., Eigentler, T., Garbe, C., Röcken, M., Hölmich, L. R., Schmidt, H., Klyver, H., Bastholt, L., et al. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2011.303 · Cited by 39
Germline Variation Controls the Architecture of Somatic Alterations in Tumors
Dworkin, A. M., Ridd, K., Bautista, D., Allain, D. C., Iwenofu, O. H., Roy, R., Bastian, B. C., & Toland, A. E. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1001136 · Cited by 39
Self-citationMithani, S. K., Smith, I. M., & Califano, J. A. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e328344a003 · Cited by 39
Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers
Yadav, V., Chen, S.-H., Yue, Y. G., Buchanan, S. G., Beckmann, R. P., & Peng, S.-B. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.12.003 · Cited by 39
Kvaskoff, M., Pandeya, N., Green, A. C., Perry, S., Baxter, C., Davis, M., Mortimore, R. J., Westacott, L., Wood, D., Triscott, J., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0475 · Cited by 39
Systemic therapy of metastatic melanoma: on the road to cure.
Bhatia, S., Tykodi, S. S., Lee, S. M., & Thompson, J. A. (2015) · PubMed · Cited by 39
Kozma, B., & Eide, M. J. (2014) · Dermatologic Clinics · doi:10.1016/j.det.2014.03.004 · Cited by 41
Genetic Mutations Involved in Melanoma: A Summary of Our Current Understanding
High, W. A., & Robinson, W. A. (2007) · Advances in Dermatology · doi:10.1016/j.yadr.2007.07.009 · Cited by 40
Imatinib in Melanoma: A Selective Treatment Option Based on KIT Mutation Status?
Becker, J. C., Bröcker, E., Schadendorf, D., & Ugurel, S. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.9664 · Cited by 39
Self-citationMimeault, M., & Batra, S. K. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00885.x · Cited by 38
“Particularly, inherited or somatic events including an inactivation of tumour suppressor genes such as p16 INK4A , p19 ARF , p53 and PTEN and/or activating mutations in KIT, H-Ras, N-Ras or B-Raf (v-Raf murine sarcoma viral oncogene homologue B1) combined with a sustained activation of diverse signalling elements incl…”
Background(2010) · PubMed · Cited by 38
Vujic, I., Posch, C., Sanlorenzo, M., Yen, A., Tsumura, A., Kwong, A., Feichtenschlager, V., Lai, K., Arneson, D. V., Rappersberger, K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2326 · Cited by 38
Dudley, J. C., Gurda, G. T., Tseng, L., Anderson, D. A., Chen, G., Taube, J. M., Gocke, C. D., Eshleman, J. R., & Lin, M. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-014-0091-6 · Cited by 38
High‐throughput sequencing of the melanoma genome
Kunz, M., Dannemann, M., & Kelso, J. F. (2012) · Experimental Dermatology · doi:10.1111/exd.12054 · Cited by 38
The immune‐related role of BRAF in melanoma
Tomei, S., Bedognetti, D., Giorgi, V. D., Sommariva, M., Civini, S., Reinboth, J., Hashmi, M. A., Ascierto, M. L., Liu, Q., Ayotte, B. D., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.014 · Cited by 38
Brachelente, C., Cappelli, K., Capomaccio, S., Porcellato, I., Silvestri, S., Bongiovanni, L., Maria, R. D., Supplizi, A. V., Mechelli, L., & Sforna, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-06281-1 · Cited by 38
Foppen, M. H. G., Boogerd, W. J., Blank, C. U., van Thienen, J. V., Haanen, J. B. A. G., & Brandsma, D. (2018) · Melanoma Research · doi:10.1097/cmr.0000000000000429 · Cited by 38
The Role of Autophagy in the Resistance to BRAF Inhibition in BRAF-Mutated Melanoma
Liu, X., Wu, J., Qin, H., & Xu, J. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0565-2 · Cited by 39
Mycobacterium bovis BCG in metastatic melanoma therapy
Ruiz-Benitez, M., Bender, C. B., Oliveira, T. L., Schachtschneider, K. M., Collares, T. V., & Seixas, F. K. (2019) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-019-10057-0 · Cited by 38
From Tank to Treatment: Modeling Melanoma in Zebrafish
Frantz, W. T., & Ceol, C. J. (2020) · Cells · doi:10.3390/cells9051289 · Cited by 38
Ren, R., Krishna, S. G., Chen, W., Frankel, W. L., Shen, R. Z., Zhao, W., Avenarius, M. R., Garee, J. P., Caruthers, S., & Jones, D. M. (2020) · Modern Pathology · doi:10.1038/s41379-020-00647-z · Cited by 38
Oxidative Stress and Autophagy as Key Targets in Melanoma Cell Fate
Catalani, E., Giovarelli, M., Zecchini, S., Perrotta, C., & Cervia, D. (2021) · Cancers · doi:10.3390/cancers13225791 · Cited by 39
Issues affecting molecular staging in the management of patients with melanoma
Palmieri, G., Casula, M., Sini, M. C., Ascierto, P. A., & Cossu, A. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00091.x · Cited by 39
Case of vemurafenib‐induced Sweet's syndrome
Yorio, J. T., Mays, S. R., Ciurea, A. M., Cohen, P. R., Wang, W., Hwu, W., Gonzalez, N., Richard, J. L., & Kim, K. B. (2014) · The Journal of Dermatology · doi:10.1111/1346-8138.12430 · Cited by 38
Sharma, A. K., Madhunapantula, S. V., Gowda, R., Berg, A. S., Neves, R. I., & Robertson, G. P. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.12.019 · Cited by 38
Kerr, E. H., Hameed, O. M., Lewis, J. S., Bartolucci, A. A., Wang, D., & Said-Al-Naief, N. A. H. (2011) · International Journal of Surgical Pathology · doi:10.1177/1066896911417970 · Cited by 38
Melanocytic Nevi and the Genetic and Epigenetic Control of Oncogene-Induced Senescence
Huang, J. M., Chikeka, I., & Hornyak, T. J. (2016) · Dermatologic Clinics · doi:10.1016/j.det.2016.08.001 · Cited by 38
Molecular Diagnostics in Melanoma: Current Status and Perspectives
Dadras, S. S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0623-rar1.1 · Cited by 38
Glatz‐Krieger, K., Pache, M., Tapia, C., Fuchs, A., Savic, S., Glatz, D., Mihatsch, M. J., & Meyer, P. (2006) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-006-0167-8 · Cited by 38
Melanoma Biomarkers: Current Status and Utility in Diagnosis, Prognosis, and Response to Therapy
Haass, N. K., & Smalley, K. S. M. (2009) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256334 · Cited by 38
Hong, J. W., Lee, S., Kim, D.-C., Kim, K., & Song, K. (2014) · Annals of Dermatology · doi:10.5021/ad.2014.26.2.195 · Cited by 38
Outcomes in patients with mucosal melanomas
Keller, D. S., Thomay, A. A., Gaughan, J., Olszanski, A. J., Wu, H. G., Berger, A. C., & Farma, J. M. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23445 · Cited by 37
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
Colombino, M., Lissia, A., Capone, M., GIORGI, V. D., Massi, D., Stanganelli, I., Fonsatti, E., Maio, M., Botti, G., Caracò, C., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-202 · Cited by 37
Epidemiology of Anorectal Melanoma in the United States
Callahan, A., Anderson, W. F., Patel, S., Barnholtz‐Sloan, J. S., Bordeaux, J. S., Tucker, M. A., & Gerstenblith, M. R. (2015) · Dermatologic Surgery · doi:10.1097/dss.0000000000000579 · Cited by 38
Flaherty, K. T. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e31823e5357 · Cited by 37
Greco, A., Safi, D., Swami, U., Ginader, T., Milhem, M. M., & Zakharia, Y. (2019) · Cancers · doi:10.3390/cancers11121950 · Cited by 37
New Insights into the Role of Sphingolipid Metabolism in Melanoma
Carrié, L., Virazels, M., Dufau, C., Montfort, A., Levade, T., Ségui, B., & Andrieu‐Abadie, N. (2020) · Cells · doi:10.3390/cells9091967 · Cited by 37
Santiappillai, N. T., AbuHammad, S., Slater, A. A., Kirby, L., McArthur, G. A., Sheppard, K. E., & Smith, L. K. (2021) · Cancers · doi:10.3390/cancers13030524 · Cited by 38
NRAS mutations in primary and metastatic melanomas of Japanese patients
Uhara, H., Ashida, A., Koga, H., Ogawa, E., Uchiyama, A., Uchiyama, R., Hayashi, K., Kiniwa, Y., & Okuyama, R. (2013) · International Journal of Clinical Oncology · doi:10.1007/s10147-013-0573-2 · Cited by 37
Prevalence of BRAF and NRAS mutations in cutaneous melanoma patients in Taiwan
Sheen, Y., Liao, Y., Liau, J., Lin, M., Hsieh, Y.-C., Jee, S., & Chu, C. (2015) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2015.02.001 · Cited by 37
The Targeting of Indoleamine 2,3 Dioxygenase ‐Mediated Immune Escape in Cancer
Iversen, T. Z., Andersen, M. H., & Svane, I. M. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12320 · Cited by 37
Applications of Genomics in Melanoma Oncogene Discovery
Berger, M. F., & Garraway, L. A. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.03.005 · Cited by 37
Pathology and genetics of uveal melanoma
Griewank, K., & Murali, R. (2012) · Pathology · doi:10.1097/pat.0b013e32835c6505 · Cited by 37
Gaudy‐Marqueste, C., Madjlessi, N., Guillot, B., Avril, M., & Grob, J. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.1 · Cited by 38
Jang, H. S., Kim, J. H., Park, K. H., Lee, J. S., Bae, J. M., Oh, B. H., Rha, S. Y., Roh, M. R., & Chung, K. Y. (2014) · Annals of Dermatology · doi:10.5021/ad.2014.26.4.485 · Cited by 37
Song, N. R., Lee, E.-J., Byun, S., Kim, J., Mottamal, M., Park, J. H. Y., Lim, S. S., Bode, A. M., Lee, H. J., Lee, K. W., et al. (2013) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0134 · Cited by 37
Vemurafenibfor the treatment of melanoma
Jordan, E., & Kelly, C. M. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.737780 · Cited by 37
Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma
Johnpulle, R. A. N., Johnson, D. B., & Sosman, J. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-015-0485-6 · Cited by 37
Melanoma biomarkers: current status and vision for the future
Larson, A. R., Konat, E., & Alani, R. M. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1296 · Cited by 37
Metadata
- Authors
- Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., Pinkel, D., & Bastian, B. C.
- Affiliations
- University of California, San Francisco (US)
- Kumamoto University Hospital (JP)
- Memorial Sloan Kettering Cancer Center (US)
- Dermatopathologie Friedrichshafen (DE)
- Seoul National University (KR)
- Tohoku University (JP)
- University of Würzburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-11-17
- Volume
- 353
- Issue
- 20
- Pages
- 2135-2147
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1989121777
- Cited by
- 2,747
- References
- 38
- Citations by year
- 2026: 54 · 2025: 69 · 2024: 87 · 2023: 91 · 2022: 85 · 2021: 125 · 2020: 165 · 2019: 133 · 2018: 130 · 2017: 164 · 2016: 157 · 2015: 170 · 2014: 197 · 2013: 218 · 2012: 202
- FWCI
- 33.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research Explorer (The University of Manchester) (publishedVersion)
- Funders
- National Cancer Institute (R01CA094963, R33 CA95300, R33CA095300)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- melanoma, UV exposure, acral melanoma, mucosal melanoma, BRAF mutation, NRAS mutation, copy number alterations, CDK4, CCND1, oncogenes, tumor genetic heterogeneity, skin cancer
- MeSH terms
- Adult, Aged, Aged, 80 and over, DNA, Neoplasm, Environmental Exposure, Female, Humans, Male, Melanoma, Middle Aged, Mutation, Nucleic Acid Hybridization, Genes, ras, Risk Factors, Skin Neoplasms, Ultraviolet Rays, Signal Transduction, Genome, Human, Phosphatidylinositol 3-Kinases, Cyclin D1, Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, PTEN Phosphohydrolase, Cyclin-Dependent Kinase 4
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.